The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBIDS.L Regulatory News (BIDS)

  • There is currently no data for BIDS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

20 Sep 2013 07:00

RNS Number : 4827O
Fitbug Holdings PLC
20 September 2013
 



Fitbug Holdings Plc / Epic: FITB.L / Index: AIM / Sector: Leisure

20 September 2013

Fitbug Holdings Plc ('Fitbug' or 'the Company')

Interim Results - Continued investment leaves Fitbug well placed for strong global growth

 

Fitbug Holdings Plc, the AIM traded provider of online personal health and well-being services, announces its results for the six months ended 30 June 2013.

 

Overview

 

· Expansion into new markets in China and Australia in line with strategy to increase its presence in the global Connected Health Market

 

· Strong pipeline of new business opportunities

 

· Launch of Fitbug Orb on track for October

 

· Legal action against Fitbit Inc progressing

 

· Pre-tax loss of £1,049,000 (2012: loss of £649,000) reflecting increased investment in new fully integrated range of mobile health products and global market development

 

· New loan of £500,000, on attractive terms, agreed with NW1 Investments Limited

 

Fitbug Executive Chairman Fergus Kee said "Growth in the Connected Health Market is accelerating. With expansion into Asia and Australia, further deals in the US and our new activity and sleep tracker, the Fitbug Orb, ready for market launch in October 2013, I believe Fitbug is well placed for strong global growth."

 

Executive Chairman's Statement

 

This has been a very active period for Fitbug, which has seen us further advance and affirm our established position in the Connected Health Market. In line with the rapid development of new, particularly mobile, technology and the increasing media and consumer interest in personal health, the Connected Health Market is projected to grow very strongly over the next few years. Whilst the US market is key, this is a global trend. In particular, we are optimistic about the new opportunities that our expansion into the fast paced markets in Australia and Singapore will create.

 

In order to capitalise on these growing markets, in August 2013 we announced that the Company's proprietary digital health technology will be offered to AIA Vitality customers in Singapore following the launch of AIA Vitality, a joint venture between the largest pan-Asian life insurer AIA Group Limited ('AIA') and Discovery Holdings Limited ('Discovery') (see announcement dated 15.08.13). Discovery Vitality, which has a successful 16-year track record as the world's largest and longest-standing wellness programme, with more than 5 million customers across four continents, has been a long-standing customer of Fitbug. In order to maximise the impact of our launch into Asia, we successfully launched Fitbug's Singapore website, in conjunction with AIA Vitality, to increase our global reach and exposure. This will also be a useful marketing tool as we look to augment our regional presence going forward.

 

Following on from our successful expansion into Asia, in September 2013 we signed a Master Services Agreement ('MSA') with Leap4Life Global Inc ('Leap4Life'), a US based wellness services provider. Under the MSA, the Company's proprietary digital health technology will, as part of a Leap4Life wellbeing programme, be offered to employees of Australia's largest grocery retailer. With the programme offered to initially 150,000 employees, we are excited about the potential to significantly expand our product reach across the company.

 

In addition to our developments into new geographic regions, we remain very focussed on building upon our presence in the key US market. In the first half Fitbug signed deals with MyFitnessPal and Redbrick Health. MyFitnessPal is a leading nutrition and fitness tracking app. Powered by more than 30 million people, MyFitnessPal has developed a searchable database of over 2.5 million items, allowing nutrition tracking. Redbrick Health is a fast-growing leader in consumer health engagement and behaviour change technology. Serving large, self-insured employers and strategic distribution partners it announced record client growth in 2012.

 

In June 2013, Fitbug also announced that its fully integrated connected health products will feature on CarePass, a new interactive consumer website and mobile app launched by Aetna. Aetna is one of the leading diversified health care benefits companies in the US and serves an estimated 44 million people. CarePass offers users simple and convenient access to some of the best health and wellness mobile apps in the marketplace and as one of only twenty companies selected to be included in CarePass, Fitbug's inclusion is extremely prestigious, illustrating Fitbug's leading market position in the US connected health market. 

 

To support our ambitious growth strategy we remain focussed on developing a highly innovative product range. In line with this, we are on track for the commercial launch of our new "Fitbug Orb" activity and sleep tracker early in Q4 2013. The Fitbug Orb, previewed at the Consumer Electronics Show, will be a critical addition to our product family and I look forward to updating the market on this exciting development in due course.

 

To fund our continued development Fitbug has signed a £500,000 loan agreement ('the Loan'), with NW1 Investments Limited ('NW1'). The Loan is repayable by 31 July 2014 and will accrue interest at a rate of 5% per annum, payable on a quarterly basis. If during the term of the Loan, Fitbug undertakes an equity issue, the Loan Holder can elect to convert some or the entire Loan into new ordinary shares in Fitbug. NW1 Investments Limited is a company in which the family of David Turner and Allan Fisher, both directors of Fitbug, have a material interest. The independent directors of the Company, being Fergus Kee, Paul Landau, Andrew Brummer and Geoffrey Simmonds, consider, having consulted with Cantor Fitzgerald Europe, that the terms of the loan are fair and reasonable in so far as the shareholders are concerned. The Company is also in discussions with NW1 regarding additional Loan facilities. The funds loaned would help support the Company's continued marketing and product development.

 

Financials

 

The results for the six months to 30 June 2013 show a pre-tax loss of £1,049,000 (2012: £649,000) reflecting expansion into new markets and increased investment in new products. Cash at 30 June 2013 is £284,000 (2012: £1,136,000).

 

Corporate Update

 

The Company is currently engaged in legal action in the US against Fitbit Inc. We believe that Fitbit's use of its trademark is infringing on Fitbug's rights. The Company has asked the U.S. District Court in Northern California to order Fitbit to permanently cease use of its Fitbit mark and from engaging in conduct that is causing confusion with Fitbug's brand and services. Legal action continues to progress and the Company will update shareholders on this in due course. 

 

Outlook

 

With a strong pipeline of new business opportunities, recent expansion into Asia and Australia and the imminent launch of an exciting new product, I believe that Fitbug is well placed for future growth in the expanding global Connected Health Market.

 

 

Fergus Kee

Executive Chairman

20 September 2013

 

For further information visit www.fitbugholdings.com or contact:

 

Paul Landau/Andrew Brummer

Fitbug Holdings Plc

020 7449 1000

Mark Percy/Catherine Leftley/Katie Ratner

Cantor Fitzgerald Europe

020 7894 7000

Claire Louise Noyce / William Lynne

Hybridan LLP

020 7947 4350 / 020 7947 4361

Elisabeth Cowell/Charlotte Heap

St Brides Media & Finance Ltd

020 7236 1177

 

 

 

Consolidated statement of comprehensive income

for the period ended 30 June 2013

Unaudited 6 months

Unaudited 6 months

Audited

Year

ended

ended

Ended

30 June

30 June

31 December

2013

2012

2012

Note

£'000

£'000

£'000

Continuing operations

Revenue

461

674

1,334

Cost of sales

(281)

(268)

(524)

------------

------------

------------

Gross profit

180

406

810

Operating and administrative expenses

(1,169)

(1,040)

(2,296)

Finance income

3

-

67

Finance costs

(63)

(15)

(56)

------------

------------

------------

Loss for the period from continuing operations

(1,049)

(649)

(1,475)

Discontinued operations

Profit for the period from discontinued operations

-

-

31

------------

------------

------------

Loss for the period and total comprehensive income for the period attributable to equity holders of the parent

(1,049)

(649)

(1,444)

------------

------------

------------

Loss per share

From continuing and discontinued operations Basic (pence per share)

(0.6)

(0.4)

(0.9)

From continuing operations Basic (pence per share)

2

(0.6)

(0.4)

(0.9)

------------

------------

------------

 

 

 

Consolidated statement of changes in equity

for the six months ended 30 June 2013

 

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

Ended

Ended

Ended

30 June

30 June

31 December

2013

2012

2012

£'000

£'000

£'000

Assets

Non-current assets

Intangible assets

117

63

117

Property, plant and equipment

16

19

17

------------

------------

------------

Total non-current assets

133

82

134

------------

------------

------------

Current assets

Inventories

422

260

394

Trade and other receivables

476

293

223

Cash and cash equivalents

284

1,136

648

------------

------------

------------

Total current assets

1,182

1,689

1,265

------------

------------

------------

Total assets

1,315

1,771

1,399

------------

------------

------------

Liabilities

Non-current liabilities

Borrowings

2,584

1,372

1,856

------------

------------

------------

Total non-current liabilities

2,584

1,372

1,856

------------

------------

------------

Current liabilities

Trade and other payables

499

349

308

Borrowings

112

87

99

------------

------------

------------

Total current liabilities

611

436

407

------------

------------

------------

Total liabilities

3,195

1,808

2,263

------------

------------

------------

Net liabilities

(1,880)

(37)

(864)

------------

------------

------------

Capital and reserves

Share capital

1,685

1,685

1,685

Share premium

1,034

1,034

1,034

Retained deficit

(4,599)

(2,756)

(3,583)

------------

------------

------------

Total equity

(1,880)

(37)

(864)

------------

------------

------------

 

 

 

Consolidated Balance Sheet

at 30 June 2013

Unaudited

Unaudited

Audited

6 months

6 months

Year

Ended

Ended

Ended

30 June

30 June

31 December

2013

2012

2012

£'000

£'000

£'000

Assets

Non-current assets

Intangible assets

117

63

117

Property, plant and equipment

16

19

17

------------

------------

------------

Total non-current assets

133

82

134

------------

------------

------------

Current assets

Inventories

422

260

394

Trade and other receivables

476

293

223

Cash and cash equivalents

284

1,136

648

------------

------------

------------

Total current assets

1,182

1,689

1,265

------------

------------

------------

Total assets

1,315

1,771

1,399

------------

------------

------------

Liabilities

Non-current liabilities

Borrowings

2,584

1,372

1,856

------------

------------

------------

Total non-current liabilities

2,584

1,372

1,856

------------

------------

------------

Current liabilities

Trade and other payables

499

349

308

Borrowings

112

87

99

------------

------------

------------

Total current liabilities

611

436

407

------------

------------

------------

Total liabilities

3,195

1,808

2,263

------------

------------

------------

Net liabilities

(1,880)

(37)

(864)

------------

------------

------------

Capital and reserves

Share capital

1,685

1,685

1,685

Share premium

1,034

1,034

1,034

Retained deficit

(4,599)

(2,756)

(3,583)

------------

------------

------------

Total equity

(1,880)

(37)

(864)

------------

------------

------------

 

Consolidated cash flow statement

for the six months ended 30 June 2013

Six months

Six months

12 Months

Ended

Ended

ended

30 June

30 June

31 December

2013

2012

2012

£'000

£'000

£'000

Cash flows from operating activities

Loss before taxation

(1,049)

(655)

(1,444)

Adjustments for:

- Depreciation and amortisation

6

51

120

- Share-based payments

33

32

67

- Finance income

(3)

-

(67)

- Finance expense

63

15

56

------------

----------

------------

Cash flows from operating activities before changes in working capital and provisions

(950)

(551)

(1,268)

- (Increase) in inventories

(28)

(95)

(229)

- (Increase) in trade and other receivables

(228)

(124)

(83)

- Increase in trade and other payables

166

115

98

------------

-----------

------------

Net cash used in operations

(1,040)

(655)

(1,482)

------------

-----------

------------

Cash flow from investing activities

Purchase of property, plant and equipment

(5)

(3)

(6)

Development costs capitalised

-

-

(117)

------------

-----------

------------

Net cash used in investing activities

(5)

(3)

(123)

------------

-----------

------------

Cash flow from financing activities

Issue of ordinary shares for cash

-

580

580

Costs directly related to issue of shares

-

(28)

(28)

Loan advances

750

1,075

1,575

Loan repayments

(9)

-

-

Finance expense

(60)

(15)

(56)

------------

-----------

------------

Net cash generated from financing activities

681

1,612

2,071

------------

-----------

------------

Net (decrease)/increase in cash and cash equivalents

(364)

954

466

Cash and cash equivalents at beginning of period

648

182

182

------------

-----------

------------

Cash and cash equivalents at end of period

284

1,136

648

------------

-----------

------------

 

Unaudited notes forming part of the consolidated interim financial statements

for the six months ended 30 June 2013

 

1 BASIS OF PREPARATION

 

Fitbug Holdings plc is a company incorporated in the United Kingdom under the Companies Act 2006. Its registered office address is 1st Floor Waterside House, 47-49 Kentish Town Road, London NW1 8NX.

 

The condensed consolidated interim financial statements of the company for the six months ended 30 June 2013 comprise the company and its subsidiaries (together referred to as "the group"). These interim statements do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The interim financial information has been prepared using the same accounting policies, presentation, method of computation and estimation techniques as are expected to be adopted in the group financial statements for the year ending 31 December 2013 and which were adopted in the audited group financial statements for the year ended 31 December 2012.

 

The financial information for the year ended 31 December 2012 has been extracted from the statutory accounts for that period. The auditors have reported on the statutory accounts for the year ended 31 December 2012 and their report was unqualified. The auditors' report drew attention by emphasis of matter to issues surrounding the ability of the company to continue as going concern. A copy of those financial statements has been filed with the Registrar of Companies. 

 

The condensed consolidated interim financial statements have been prepared using accounting policies consistent with International Financial Reporting Standards (IFRSs) as adopted in the EU. While the financial figures included in this half yearly report have been computed in accordance with IFRSs as adopted in the EU applicable to interim periods, this half yearly report does not contain sufficient information to constitute an interim financial report as that term is defined in IAS 34.

 

 

2 LOSS PER SHARE

 

The loss per share from continuing and discontinued operations is based on a loss for the period attributable to equity holders of the Parent Company of £1,049,000 (2012 - loss of £649,000) and the weighted average number of ordinary shares being in issue for the period of 168,515,007 (2012 - 152,136,461).

 

The exercise of the outstanding options would reduce the loss per share and hence have an anti-dilutive effect. There are 13,000,000 (2012: 13,300,000) shares that could potentially be issued under the terms of options that will potentially reduce future earnings per share.

 

 

3 GOING CONCERN

The condensed interim financial statements for the six months ended 30 June 2013 have been prepared on the assumption that the group will be able to continue trading as a going concern for the foreseeable future. At 30 June 2013 the group had net liabilities of £1,880,000, which includes loans of £2,250,000 from Kifin Limited, a Kirsh Group subsidiary, including a £1,000,000 loan issued under a convertible loan note instrument dated 28 June 2013. This facility has a term of three years to 30th June 2015 and accrues interest at a rate of 5% per annum, payable in arrears at the end of the first year and quarterly thereafter. The loan note is convertible by the holder, at any time, into 66,666,667 ordinary shares in Fitbug at a price of 1.5 pence per ordinary share. The other loans are repayable by 31 July 2014 and accrue interest at a rate of 5% per annum, payable on a quarterly basis.

 

The group also has a £372,000 loan from NW1 Investments Limited, a company connected to two of the directors of the Group.

 

Post period end, Fitbug Holdings plc agreed a £500,000 loan from NW1 Investments Limited which is repayable by 31 July 2014 and will accrue interest at a rate of 5% per annum, payable on a quarterly basis. The Group is also currently in discussions with NW1 Investments Limited regarding a further loan facility.

 

The directors have prepared financial forecasts which suggest that, based on anticipated sales pipeline, the Group has sufficient facilities to meet its working and development capital requirements.

 

The directors have continued to adopt the going concern concept in preparing these interim financial statements on the basis that they believe that the anticipated sales pipeline and a number of opportunities currently available to them will generate improved revenue and profitability. The sales forecasts are however based on the achievement of and timings of revenue forecasts which, although believed reasonable by the directors are nevertheless, in part, outside the Group's direct control. If significant delays were to take place, these may render the Group's cash resources insufficient.

 

If as a result the Group were unable to continue as a going concern, then adjustments would be necessary to write assets down to their recoverable amounts, non-current assets and liabilities would be reclassified as current assets and liabilities and provisions would be required for any costs associated with closure.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LFFEIAVIALIV
Date   Source Headline
23rd Apr 20247:00 amRNSCancellation - Bidstack Group PLC
22nd Mar 20241:11 pmRNSAppointment of Administrators & Nomad Resignation
11th Mar 20247:30 amRNSSuspension - Bidstack Group PLC
11th Mar 20247:00 amRNSIntention to Appoint Administrators & Suspension
5th Feb 20247:00 amRNSUpdate on CLN, Financial Update & Strategic Review
22nd Dec 20237:00 amRNSSettlement & new commercial partnership - Azerion
1st Nov 20237:00 amRNSChange of Registered Office
18th Oct 20233:45 pmRNSProposed CLN, Share Reorganisation and VST Update
29th Sep 20237:00 amRNSBoard Change
29th Sep 20237:00 amRNSProposed New Commercial Partnership
29th Sep 20237:00 amRNSInterim Results
30th Aug 20237:00 amRNSVenatus Advertising Sales Partnership
23rd Aug 20234:47 pmRNSTR-1: Notification of Major Holdings
21st Jul 202311:23 amRNS2023 Annual General Meeting Results
18th Jul 202311:46 amRNSGeneral Meeting Requisition Request withdrawn
18th Jul 20237:00 amRNSBoard Changes
13th Jul 20231:32 pmRNSVirtual stadium partnership with first NFL team
11th Jul 20237:00 amRNSRequisitioned General Meeting
5th Jul 20237:00 amRNSRequest to requisition a General Meeting
21st Jun 20237:00 amRNSAnnual Report & Accounts and Notice of AGM
20th Jun 20238:18 amRNSFinal Results and Annual Report - replacement
20th Jun 20237:00 amRNSAnnual Report & Accounts and Notice of AGM
1st Mar 20235:28 pmRNSComment on Azerion Statement
15th Feb 20237:00 amRNSBidstack appoints Thomas Bullen as CFO
13th Feb 20232:05 pmRNSSecond Price Monitoring Extn
13th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 20237:00 amRNSTrading and Operational Update
18th Jan 202311:22 amRNSChange of Registered Office
3rd Jan 202311:05 amRNSSecond Price Monitoring Extn
3rd Jan 202311:00 amRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSAzerion Update
29th Dec 20227:00 amRNSBoard Changes
9th Dec 202211:04 amRNSGrant of LTIP Options
8th Dec 20227:00 amRNSExercise of Options, Issue of Equity & TVR
6th Dec 202211:03 amRNSTR-1: Notification of major holdings
5th Dec 20227:00 amRNSBidstack adds 2 titles with a AAA game publisher
1st Nov 20223:39 pmRNSTR-1: Notification of major holdings
31st Oct 20223:35 pmRNSTotal Voting Rights
31st Oct 20223:21 pmRNSTR-1: Notification of major holdings
31st Oct 20222:16 pmRNSTR-1: Notification of major holdings
31st Oct 202211:54 amRNSTR-1: Notification of major holdings
28th Oct 20224:16 pmRNSTR-1: Notification of Major Holdings
28th Oct 20227:00 amRNSUpdate re Press Commentary
26th Oct 20223:45 pmRNSAdmission of Ordinary Shares and TVR
26th Oct 20227:00 amRNSStrategy Update
25th Oct 202212:08 pmRNSResults of General Meeting
13th Oct 20227:00 amRNSBidstack appoints Camila Franklin as COO
6th Oct 20226:28 pmRNSResults of REX Retail Offer
6th Oct 20228:06 amRNSResults of Placing and Subscription
5th Oct 20224:36 pmRNSREX Retail Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.